SecBot SecBot
8-K ·Filed Apr 13, 2026

PVLA

PALVELLA THERAPEUTICS, INC.
NEUTRAL
Impact 3/10
Horizonweeks Processed7mo ago SEC0001193125-26-151979
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

The appointment adds biopharma governance and investment expertise to the board. Traders should monitor for potential strategic shifts given Dr. Doux’s background in rare disease therapeutics and prior board experience, though no immediate changes are indicated.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$129.00
T+0 close · Apr 13, 2026 · via day close
Latest settled
+12.55%
T+60 · $145.19
Vs SPY
+3.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $129.00entry
  2. T+1 · 7mo ago +0.41%α −0.80% · $129.53
  3. T+5 · 7mo ago +0.26%α −3.04% · $129.33
  4. T+20 · 6mo ago −5.36%α −13.08% · $122.09
  5. T+60 · 4mo ago +12.55%α +3.63% · $145.19
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palvella Therapeutics appointed John Doux, M.D., to its Board of Directors as a Class III member, effective April 13, 2026. Dr. Doux brings extensive experience in dermatology, biotech investing, and corporate governance from prior board roles in healthcare companies.

Key Facts

  • John Doux, M.D., was appointed to the Board of Directors effective April 13, 2026
  • Board size increased from six to seven members
  • Dr. Doux is a board-certified dermatologist and healthcare investor at Palo Alto Investors LP
  • He previously served on Palvella's board from 2019 to 2022 prior to its reverse merger
  • No departures or executive officer changes announced
  • Dr. Doux received an option grant to purchase 6,000 shares, vesting monthly over 36 months

Financial Impact

Minimal near-term financial impact; option grant for 6,000 shares represents minor potential dilution

share_countcompensation_expense

Risk Factors

  • Minimal execution risk as this is a board expansion, not a C-suite change
  • Potential for increased investor scrutiny due to Dr. Doux’s analytical background

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-151979
Document: 0001193125-26-151979-index-headers.html0001193125-26-151979
Document: 0001193125-26-151979-index.html0001193125-26-151979
Document: 0001193125-26-151979.txt0001193125-26-151979

Track record

36 reports on PVLA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026